by Plus Therapeutics | Dec 4, 2025 | Uncategorized
Plus Therapeutics is pleased to announce the presentation of three positive clinical data updates at the World Federation of Neuro-Oncology Societies (WFNOS) / Society for Neuro-Oncology (SNO) 2025 Annual Meeting. These new findings advance the Company’s growing body...
by Plus Therapeutics | Dec 3, 2025 | Uncategorized
Plus Therapeutics’ growing momentum in central nervous system (CNS) oncology was recently spotlighted when President & CEO Marc Hedrick, MD, joined host Ira S. Pastor on the Progress, Potential, and Possibilities podcast. The in-depth discussion provides a clear,...
by Plus Therapeutics | Dec 1, 2025 | LM
Plus Therapeutics is pleased to announce that its abstract has been accepted for a Poster Spotlight with Oral Presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS 2025), taking place December 9–12, 2025, in San Antonio, Texas. This recognition...
by Plus Therapeutics | Nov 26, 2025 | GBM
Innovations in brain cancer treatment continue to advance, fueled by the dedication of leading clinicians and researchers across the globe. In the latest episode of the Game On Glio podcast, Toral Patel, MD (UT Southwestern Medical Center) and Andrew Brenner, MD, PhD...
by Plus Therapeutics | Nov 24, 2025 | LM
Plus Therapeutics announced that it has successfully completed a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company’s clinical development plans for REYOBIQ™, its targeted radiotherapeutic for leptomeningeal metastases (LM). The...
Recent Comments